Firms

WuXi AppTec

Shanghai, China · Wuxi, Jiangsu, China

WuXi AppTec is the publicly listed pharmaceutical research, development and manufacturing corporate group led by WuXi AppTec Co., Ltd., a PRC joint-stock company listed on the Shanghai Stock Exchange (603259) and Hong Kong Stock Exchange (2359). Founded in2000, it provides an integrated CRDMO platform for discovery, development and commercial manufacturing of small-molecule drugs and emerging modalities including peptides and oligonucleotides, with operations across Asia, Europe and North America. Its own filings describe investment in AI-enabled drug discovery, lab automation, healthcare data and robotic chemistry. Ge Li is chairman and CEO, with co-CEOs Minzhang Chen and Steve Qing Yang. The current public directory publishes17 senior operational leaders; current HKEX filings separately identify11 board directors and company secretaries. WuXi AppTec also makes strategic corporate investments, including Engine Biosciences. It is a corporate operating platform and investor, not an independent VC fund; the legacy immutable InvestmentFirm type and Investor3651 are preserved to retain all historical references. WuXi Biologics (Cayman) Inc. is a separate listed issuer (2269.HK), and WuXi Healthcare Ventures is a separate existing investor record; neither is merged or substituted as the buyer. Corporate securities proceeds, cumulative investment balances and acquisitions are not external LP fund closes.

Founded: 2000
Type: Venture capital

Funds0

No funds on record yet.

Team

Operations and support

Cheung Yuet FanJoint Company Secretary (external Tricor/Vistra service provider)

Christine Shaohua Lu-WongIndependent Non-executive Director; Audit Committee Chair

Dirk TormansSenior Vice President, WuXi Chemistry Global QA

Feng Zhang (WuXi AppTec)Senior Vice President, API Manufacturing

Ge Li WuXi FounderChairman, Executive Director and CEO

Hao WuSenior Vice President, Legal Department, Human Resources Department

Jinling ChenSenior Vice President, Pharmaceutical Development and Manufacturing

Ke ChenSenior Vice President, API Late Phase Development and Commercialization

Min HanBoard Secretary and Joint Company Secretary

Ming ShiSenior Vice President, Chief Financial Officer

Minzhang ChenExecutive Director and Co-CEO

Richard ConnellUS/EU President

Steve Qing YangExecutive Director and Co-CEO

Tao GuoSenior Vice President, RCS IPM

Wei YuLead Independent Non-executive Director

Xiang WuSenior Vice President, RCS

Xiaomeng TongNon-executive Director

Xiaoyong FuExecutive Vice President, STA

Xin ZhangIndependent Non-executive Director

Xuanjia PengSenior Vice President, WuXi Testing, WuXi Biology, Automation Department

Xuesong LengIndependent Non-executive Director; Nomination Committee Chair

Yibing WuNon-executive Director

Youchu WangSenior Vice President, API Early Phase Development

Yu LuSenior Vice President, WuXi TIDES, WuXi Chemistry Business Operations

Zhaohui ZhangExecutive Director, Executive Vice President and China Chief Operating Officer

Zhiling ZhanIndependent Non-executive Director; Remuneration and Appraisal Committee Chair

Investments

$59M2023	Cutia	Sequoia, Fidelity Investments, WuXi AppTec, Yunfeng Capital, WuXi Healthcare Ventures
$43M2021-05-26	Engine Biosciences	Polaris Partners, 6 Dimensions Capital, DHVC (Danhua Capital), Nest.Bio Ventures, EDBI, WI Harper Group, Baidu Ventures, WuXi AppTec, Vectr Ventures, The Invus Group, LLC, Goodman Capital
$110M2019-05-19	Schrödinger	WuXi AppTec, The Invus Group, LLC, Laurion Capital Management, Deerfield, GV, Pavilion Capital
$32M2018-07-16	Verge Genomics	Y Combinator, OS Fund, DFJ Growth, WuXi AppTec, Lifeforce Capital, Agent Capital
$260M2018-05-09	CStone Pharmaceuticals	ARCH Venture Partners, 6 Dimensions Capital, WuXi AppTec, Boyu Capital, Yunfeng Capital, CPE
$10M2018-01-31	Engine Biosciences	6 Dimensions Capital, DHVC (Danhua Capital), Pavilion Capital, Nest.Bio Ventures, EDBI, WI Harper Group, Baidu Ventures, WuXi AppTec
$55M2017-09-18	LifeMine Therapeutics	ARCH Venture Partners, MRL Ventures Fund, Alexandria Venture Investments, GV, WuXi AppTec, Boyu Capital

team@apexlogos.ai17 hours ago
Corporate legal identity and capital-raising audit: WuXi AppTec Co., Ltd. is a PRC listed operating corporation; its inherited MCP InvestmentFirm type is immutable. Actual issuer securities raises are documented here rather than manufacturing a duplicate Company or external VC LP fund. Official2025annual pages73–77 confirms: 2020 new H-share placing completed2020-08-05, approximately HKD7,287.3M net proceeds (RMB6,558.6M converted); 2025 new H-share placing completed2025-08-07, 73,800,000 shares at HKD104.27, derived grossHKD7,695,126,000, disclosed netHKD7,647.4M (rounded table). Placing agents are not inferred investors. WuXi AppTec(Hong Kong)Limited issued USD500M convertible bonds completed2024-10-21, parentguaranteed, netUSD494.4M; the2025-10-10 conversion into49,600,759 parentHshares is not fresh cash. Initial A/H IPO and A-share nonpublic issuance were actual historical financings, but this audit has not independently retrieved exact original cash/date filings, so no guessed values added. No new external LP fund closes created; internal Corporate Venture Fund branding does not alone identify a distinct legal LP vehicle or closed size. WuXi Biologics and historical WuXi Healthcare Ventures/6Dimensions remain separate buyers. Source: https://www.hkexnews.hk/listedco/listconews/sehk/2026/0401/2026040101920.pdf

Funds0

Team

Operations and support

Co-investing

Investments